Varicella zoster vaccination;Vacunación frente al herpes zóster

Vacunas

Volumn 11, Issue 3, 2010, Pages 110-120

  Salleras, L ^a   Salleras, M ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

DRUG EFFICACY; DRUG TOLERABILITY; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VACCINATION;

EID: 78649266513     PISSN: 15769887     EISSN: 15788857     Source Type: Journal    
DOI: 10.1016/S1576-9887(10)70023-6     Document Type: Review

References (47)

1. a ed. 2003 Masson Barcelona 311 330
2. J.W. Gnann Jr, and R.J. Whitley Hespes zoster N Engl J Med 347 2002 340 346
3. J.M. Weinberg Herpes zoster: Epidemiology, natural history and common complications J Am Acad Dermatol 57 2007 S130 S135
4. A.A. Gershon, M. Takahashi, and J. Seward Varicella vaccine S.A. Plotkin, W.A. Orenstein, Vaccines 4th ed. 2004 WB Saunders Philadelphia 783 824
5. M. Holodniy Prevention of shingles by varicella zoster virus vaccination Expert Rev Vaccines 5 2006 431 443
6. L. Salleras, and M. Salleras Historia natural de la infección por el virus de la varicela zóster Vacunas 10 2009 125 129
7. L. Salleras, and M. Salleras Epidemiología del herpes zóster Vacunas 11 2010 80 81
8. CDC. Prevention of Varicella Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 45 1996 1 36
9. L. Salleras, M. Salleras, M. Prat, P. Garrido, and A. Domínguez Vacunas frente al virus de la varicela zóster Enferm Infecc Microbiol Clin 25 Supl. 4 2007 29 47
10. P.A. Brunell, J. Taylor-Wiedeman, C.F. Geiser, L. Frierson, and E. Lydick Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox Pediatrics 77 1986 53 56
11. I. Hardy, A.A. Gershon, S.P. Steinberg, and P. LaRussa The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group N Engl J Med 325 1991 1545 1550
12. R. Lawrence, A.A. Gershon, R. Holzman, and S.P. Steinberg The risk of zoster after varicella vaccination in children with leukemia N Engl J Med 318 1988 543 548
13. H.F. Tseng, N. Smith, S.M. Marcy, L.S. Sy, and S.J. Jacobsen Incidence of herpes zoster among children vaccinated with varicella vaccine in a prepaid health care plan in the United States 2002-2008 Pediatr Infect Dis J 28 2009 1069 1072
14. R. Civen, S.S. Chaves, A. Jumaan, H. Wu, L. Mascola, and P. Gargiullo The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination Pediatr Infect Dis 28 2009 954 959
15. M.N. Oxman, M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, and L.D. Gelb A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2005 2271 2284
16. A.E. Miller Selective decline in cellular immune response to varicella-zoster in the elderly Neurology 30 1980 582 587
17. R. Berger, G. Florent, and M. Just Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged Infect Immun 32 1981 24 27
18. B.L. Burke, R.W. Steele, O.W. Beard, J.S. Wood, T.D. Cain, and D.J. Marmer Immune response to varicella-zoster in the aged Arch Intern Med 142 1982 291 293
19. M.W. Ragozzino, L.F. Melton III, L.T. Kurland, C.P. Chu, and H.O. Perry Population-based study of herpes zoster and its sequelae Medicine (Baltimore) 61 1982 310 316
20. J.G. Donahue, P.W. Choo, J.E. Manson, and R. Platt The incidence of herpes zoster Arch Intern Med 155 1995 1605 1609
21. M.N. Oxman Immunization to reduce the frequency and severity of herpes zoster and its complications Neurology 45 Suppl 8 1995 S41 S46
22. M.J. Levin Use of varicella vaccines to prevent herpes zoster in older individuals Arch Virol Suppl 17 2001 151 160
23. M.J. Levin, M. Murray, H.A. Rotbart, G.O. Zerbe, J. White, and A.R. Hayward Immune response of elderly individuals to a live attenuated varicella vaccine J Infect Dis 166 1992 253 259
24. M.J. Levin, D. Barber, E. Goldblatt, M. Jones, B. LaFleur, and C. Chan Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect J Infect Dis 178 Suppl 1 1998 S109 S112
25. E. Trannoy, R. Berger, G. Hollander, F. Bailleux, P. Heimendinger, and D. Vuillier Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial Vaccine 18 2000 1700 1706
26. Levin MJ, Hayward AR. Prevention of herpes zoster. En: Ellis P, White CJ, editors. Infect Dis Clin N.A. 1996;10:657-76.
27. CDC. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 57 2008 21 31
28. European Medicines Agency: Zostavax. Disponible en: www.emea.eu/ humandocs/PDFs/EPAR/zostavax/067406en6.pdf.
29. M.J. Levin, J.G. Smith, R.M. Kaufhold, D. Barber, A.R. Hayward, and C.Y. Chan Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine J Infect Dis 188 2003 1336 1344
30. M.J. Levin, M.N. Oxman, J.H. Zhang, G.R. Johnson, H. Stanley, and A.R. Hayward Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine J Infect Dis 197 2008 825 835
31. A. Weinberg, J.H. Zhang, M.N. Oxman, G.R. Johnson, A.R. Hayward, M.J. Caulfield US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine J Infect Dis 200 2009 1068 1077
32. L.I. Gilderman, J.F. Lawless, T.M. Nolen, T. Sterling, R.Z. Rutledge, D.A. Fernsler Zostavax Protocol 010 Study Group A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax Clin Vaccine Immunol 15 2008 314 319
33. B. Kerzner, A.V. Murray, E. Cheng, R. Ifle, P.R. Harvey, and M. Tomlinson Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older J Am Geriatr Soc 55 2007 1499 1507
34. S.C. Sutradhar, W.W. Wang, K. Schlienger, J.E. Stek, J. Xu, I.S. Chan, and J.L. Silber Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and adults 60 years and older Clin Vaccine Immunol 16 2009 646 652
35. C.R. MacIntyre, T. Egerton, and M. McCaughey Concomitant administration of zoster and pneumococcal vaccines in adults ≥ 60 years old [abstract no.G-399d plus poster] 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, Washington, D. C 2008
36. Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, et al. Safety, tolerability and immunogenicity of zoster vaccine in subjects with a history of herpes zoster (HZ). Vaccine. 2010.[En prensa].
37. K.E. Schmader, A.M. Bobrove, and M.J. Levin Immunogenicity and safety of varicella-zoster virus (VZV) vaccine administered to older adults with or without diabetes mellitus (DM) or chronic obstructive pulmonary disease (COPD) [abstract no D26 plus poster] 2006 American Geriatrics Society Annual Meeting May 3-7; Chicago (IL) 2006
38. K.E. Schmader, M.N. Oxman, and M.J. Levin Persistence of zoster vaccine efficacy [abstract no G-409 plus poster] 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, Washington, D. C 2008
39. M.B. Rothberg, A. Virapongse, and K.J. Smith Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Clin Infect Dis 44 2007 1280 1288
40. J.M. Pellissier, M. Brisson, and M.J. Levin Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Vaccine 25 2007 8326 8337
41. J. Hornberger, and K. Robertus Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Ann Intern Med 145 2006 317 325
42. A.J. Van Hock, N. Gay, and A. Melegaro Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales Vaccine 27 2009 1454 1467
43. M.B. Brisson, J.M. Pellisier, S. Camden, C. Quach, and P. De Wals The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia Hum Vaccin 4 2008 238 245
44. M. Najafzadeh, C.A. Marra, E. Galanis, and D.M. Patrick Cost effectiveness of herpes zoster vaccine in Canada Pharmacoeconomics 27 2009 991 1004
45. W.J. Edmuns, M. Brisson, and J.D. Rose The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales Vaccine 19 2001 3076 3090
46. S. Márquez-Peláez, and J. Ruiz-Aragón Revisión sistemática de los estudios económicos sobre la vacuna contra el herpes zoster y la neuralgia postherpética en adultos Vacunas 10 2009 118 124
47. M. Brisson Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality Can J Public Health 99 2008 383 386